Region: Global
Category: Cancer Treatment

Global Cancer Treatment

(1,260 reports matching your criteria)
  • Global Pancreatic Cancer Market - 2024 - 2031

    ... to exhibit a CAGR of 11.1% during the forecast period (2024-2031). Chemotherapy medications are used to kill or stop cancer cell division. Adjuvant chemotherapy is administered after surgery to eradicate any cancer cells left over, ... Read More

  • Global Thymus Cancer Market - 2023-2030

    ... expected to exhibit a CAGR of 5.5% during the forecast period (2024-2031). The key players are adopting strategies such as partnerships, mergers, acquisitions, novel product launches and enhanced focus on R&D and regional expansion to ... Read More

  • Global Cancer Tumor Profiling Market - 2024 - 2031

    ... is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on ... Read More

  • Global Difficult-to-Express Proteins Market - 2023-2030

    ... to exhibit a CAGR of 11.0% during the forecast period (2024-2031). Prokaryotic expression system research and development have increased due to the rising demand for recombinant proteins and this trend is anticipated to fuel market ... Read More

  • Global Oral Transmucosal Drugs Market- 2023-2030

    ... to exhibit a CAGR of 6.4% during the forecast period (2023-2030). Oraltransmucosal drug administration was an alternative route in end-of-life care and palliative care during the COVID-19 pandemic. Oral transmucosal drug delivery is the systemic ... Read More

  • Global Colorectal Cancer Drugs Market - 2024 - 2031

    ... Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2024-2031. The treatment of colorectal cancer typically involves a combination of surgery, radiation therapy, and chemotherapy. Besides, the treatment regimens for ... Read More

  • Liquid Biopsy For Cancer Diagnostics Global Market Opportunities And Strategies To 2034 Including: 1) By Type: Product; Services 2) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer 3)By Sample: Blood; Urine; Saliva 4) By End User: Hospitals; Diagnostic Centers Covering: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Guardant Health Inc.; Illumina Inc.; Exact Sciences Corporation

    ... biopsy for cancer diagnostics market as it emerges from the COVID-19 shut down. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies. Understand how ... Read More

  • 2025 Neoplasms Global Market Size & Growth Report with Updated Analysis & Forecasts

    ... countries. Figures are from 2013 through 2024, with forecasts for 2025 and the next 5 years. The historical data utilizes in-depth survey results from companies selling neoplasms (tumors) (c00-d49). The survey data is combined with ... Read More

  • Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

    ... by many rising impacts with respect to improving cases of respiratory diseases around the world. Innovative technologies in diagnosis, such as molecular diagnostics and advanced imaging solutions, have also improved the accuracy and speed of ... Read More

  • Global Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030)

    ... & Inflammatory Diseases, Other Indications), By Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccines) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The report analyses the Immunotherapy Drugs Market ... Read More

  • mRNA Platform

    ... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine Indication, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the ... Read More

  • Breast Cancer Screening

    ... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More

  • Cancer Gene Therapy

    ... at a CAGR of 20.9% over the analysis period 2024-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.7% CAGR and reach US$4.3 Billion by the end of ... Read More

  • Nano-Magnetic Devices

    ... CAGR of 5.4% over the analysis period 2024-2030. Nano-Magnetic Sensors, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$12.8 Billion by the end of the analysis ... Read More

  • Microwave Ablation

    ... CAGR of 13.2% over the analysis period 2024-2030. Liver Cancer Application, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$215.5 Million by the end of the ... Read More

  • Oncology Based In-Vivo CRO

    ... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More

  • Cancer Stem Cells

    ... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More

  • Cancer Supportive Care

    ... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More

  • Kaposi Sarcoma

    ... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More

  • Oncology Information Systems

    ... at a CAGR of 6.2% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$5.5 Billion by the end of ... Read More

  • Colorectal Cancer Therapeutics

    ... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More

  • Particle Therapy

    ... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More

  • Cervical Cancer Diagnostic Testing

    ... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by ... Read More

  • In-Vitro Colorectal Cancer Screening Tests

    ... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More

  • Cancer Diagnostics

    ... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More

< prev 1 2 3 4 5 6 7 8 9 10

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings